FDA approves first treatment for congenital athymia
Congenital athymia is a rare condition in which babies are born without a thymus. As a result, the immune...
FDA
FDA Approves Pradaxa (Dabigatran Etexilate), the First Oral Anticoagulant for Children
The Food and Drug Administration approves Boehringer Ingelheim’s Pradaxa (dabigatran etexilate) oral pellets to treat venous thromboembolism (VTE) in children aged 3...
IpsiHand Stroke Rehab System Receives FDA Market Authorization
FDA has authorized marketing for the first-of-its-kind device to assist upper limb rehabilitation of stroke patients.1 In 2017, a...
FDA Approves First Trial of CRISPR for Sickle Cell Disease
The U.S Food and Drug Administration (FDA) has approved the first clinical trial of CRISPR to correct sickle cell...
First-in-class drug approved for bone marrow protection during chemotherapy
Chemotherapy can be lifesaving, but it can also damage bone marrow and cause blood cell counts to drop, sometimes...
FDA approves Qelbree, a Non-stimulant Treatment for ADHD
The FDA has approved Qelbree (SPN-812), for children aged 6 to 17 years with attention deficit hyperactivity disorder (ADHD)....
US FDA Approves Midostaurin for Treatment of Acute Myeloid Leukemia
The US FDA approved the use of Rydapt (midostaurin) in combination with chemotherapy for treating recently diagnosed adults with...
Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL) by the FDA
Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is not breast cancer but a rare type of T-cell lymphoma that...
FDA Issues Warning Regarding the Use of Balloon Angioplasty For Treatment Of Autonomic Dysfunction Disorders
US Food and Drug Administration (FDA) has warned both patients and doctors alike about the use of balloon angioplasty...
FDA gives a green signal for maintenance treatment of recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer with Niraparib
Adult patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who have responded completely or partially to...